Brookline Capital Markets Remains a Buy on Syros Pharmaceuticals (SYRS)

Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on Syros Pharmaceuticals (SYRSResearch Report) today and set a price target of $60.00. The company’s shares closed yesterday at $0.73.

R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and Syros Pharmaceuticals. According to TipRanks, R. Cann has an average return of -1.6% and a 38.89% success rate on recommended stocks.

Currently, the analyst consensus on Syros Pharmaceuticals is a Strong Buy with an average price target of $18.25.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $5.20 and a one-year low of $0.65. Currently, Syros Pharmaceuticals has an average volume of 1.5M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Read More on SYRS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More